Skip to main content
Institute of Population Health Sciences (IPHS)

Doris Lanz


BARC Senior Trials Manager

Telephone: 020 7882 5636


Doris oversees the development and conduct of BARC studies (EMmY, OMAhA, MERIT, TILT, ACROBAT) and helps with the organisation of Katie’s Team, our patient and public involvement group. She has previously coordinated the SALVO trial (Cell Salvage in Obstetrics) and has experience as a coordinator and QA officer in a variety of other clinical areas such as cancer research, mental health and bowel disease.



Russell J, Berney L, Stansfeld S, Lanz D, Kerry S, Chandola T, Bhui K. The role of qualitative research in adding value to a randomised controlled trial: lessons from a pilot study of a guided e-learning intervention for managers to improve employee wellbeing and reduce sickness absence. Trials; 2016 Aug 9;17(1):396. PubMed PMID: 27507134.

Stansfeld SA, Berney L, Bhui K, Chandola T, Costelloe C, Hounsome N, Kerry S, Lanz D, Russell J. Pilot study of a randomised trial of a guided e-learning health promotion intervention for managers based on management standards for the improvement of employee well-being and reduction of sickness absence: the GEM (Guided E-learning for Managers) study. Southampton (UK): NIHR Journals Library; 2015 Aug. PubMed PMID: PMID: 26269873

Von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). Onkologie. 2010;33(6):295-9.  PubMed PMID: 20523092.

Schuller JC, Mayer M, Lanz D, Schmitz SF, Brauchli P, Leupin N. A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials. Contemp Clin Trials. 2009 May;30(3):201-4. PubMed PMID: 19470310.

Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B, Caspar C, Ruhstaller T, Roth A, Kappeler A, Dietrich D, Lanz D, Mingrone W. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol. 2008 Jul;19(7):1288-92. PubMed PMID: 18349029.

Gick U, Rochlitz C, Mingrone W, Pestalozzi B, Rauch D, Ballabeni P, Lanz D, Hess V, Aebi S. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. Oncology. 2006;71(1-2):54-60. PubMed PMID: 17344671.

Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol. 2005 Feb;16(2):282-8. PubMed PMID: 15668285.